EVFM - Evofem Biosciences reports Q2 results

• Evofem Biosciences press release ( NASDAQ: EVFM ): Q2 loss from operations improved 16% to $24.4M.
• Revenue of $6M (+215.8% Y/Y) misses by $0.05M .
• Evofem ( EVFM ) continues to expect net product sales in the range of $30M to $35M for its 2022 fiscal year, representing 264% to 325% growth year-over-year vs. consensus of $31.34M. Gross-to-net is expected to be 40% or better, trending toward the lower in the second half of the year. The company remains on track to meet its goal of reducing costs by $50M in 2022; total operating expenses were $25.3M lower in the first half of 2022 versus the same period last year.

For further details see: